Participant flow. M:F, ratio of males to females; NA, not applicable. *, two subjects from the Mtb72F (40 μg)/AS02A group were eliminated from the ATP immunogenicity analysis: one subject withdrew from vaccination at dose 3, and the other subject was out of interval for blood samples; **, one subject from the Mtb72F (40 μg)/saline group was not included in the ATP immunogenicity analysis because he moved away from the study area after dose 2.